Drug Screening Using IMD in Bladder Cancer
NCT: NCT06204614 · ENROLLING_BY_INVITATION
Brief Summary
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.
Frequently Asked Questions
What is Drug Screening Using IMD in Bladder Cancer?
Drug Screening Using IMD in Bladder Cancer is a clinical trial registered under NCT06204614. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT06204614?
The current status of NCT06204614 (Drug Screening Using IMD in Bladder Cancer) is: ENROLLING_BY_INVITATION.
When did Drug Screening Using IMD in Bladder Cancer start?
Drug Screening Using IMD in Bladder Cancer started on 2024-06-14.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.